Biogen Inc Stock Fundamentals
| IDP Stock | EUR 189.75 5.10 2.76% |
Biogen Inc fundamentals help investors to digest information that contributes to Biogen's financial success or failures. It also enables traders to predict the movement of Biogen Stock. The fundamental analysis module provides a way to measure Biogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biogen stock.
Biogen |
Biogen Inc Company Profit Margin Analysis
Biogen's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Biogen Profit Margin | 0.30 % |
Most of Biogen's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biogen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Biogen Inc has a Profit Margin of 0.2995%. This is 102.67% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The profit margin for all Germany stocks is 123.58% lower than that of the firm.
Biogen Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biogen's current stock value. Our valuation model uses many indicators to compare Biogen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biogen competition to find correlations between indicators driving Biogen's intrinsic value. More Info.Biogen Inc is rated second overall in return on equity category among related companies. It is rated third overall in return on asset category among related companies reporting about 0.32 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biogen Inc is roughly 3.13 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biogen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biogen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biogen's earnings, one of the primary drivers of an investment's value.Biogen Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biogen's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biogen could also be used in its relative valuation, which is a method of valuing Biogen by comparing valuation metrics of similar companies.Biogen is currently under evaluation in profit margin category among related companies.
Biogen Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.0778 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 41.13 B | |||
| Shares Outstanding | 144.49 M | |||
| Shares Owned By Insiders | 0.68 % | |||
| Shares Owned By Institutions | 89.93 % | |||
| Price To Earning | 14.27 X | |||
| Price To Book | 3.24 X | |||
| Price To Sales | 3.84 X | |||
| Revenue | 10.17 B | |||
| Gross Profit | 7.9 B | |||
| EBITDA | 4.36 B | |||
| Net Income | 3.05 B | |||
| Cash And Equivalents | 2.54 B | |||
| Cash Per Share | 16.85 X | |||
| Total Debt | 6.28 B | |||
| Debt To Equity | 0.72 % | |||
| Current Ratio | 2.12 X | |||
| Book Value Per Share | 92.98 X | |||
| Cash Flow From Operations | 1.38 B | |||
| Earnings Per Share | 19.22 X | |||
| Price To Earnings To Growth | 36.01 X | |||
| Target Price | 413.19 | |||
| Number Of Employees | 8.72 K | |||
| Beta | 0.22 | |||
| Market Capitalization | 36.91 B | |||
| Total Asset | 24.55 B | |||
| Z Score | 3.0 | |||
| Net Asset | 24.55 B |
About Biogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biogen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biogen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. BIOGEN INC operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 9100 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |